REVIEW

Targeting calcium signaling in cancer therapy

Chaochu Cui\textsuperscript{a,b}, Robert Merritt\textsuperscript{b,c}, Liwu Fu\textsuperscript{a}, Zui Pan\textsuperscript{b,c,d,*}

\textsuperscript{a}State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
\textsuperscript{b}Department of Surgery, Division of Thoracic Surgery, The Ohio State University, Columbus, OH 43210, USA
\textsuperscript{c}Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
\textsuperscript{d}College of Nursing and Health Innovation, The University of Texas at Arlington, Arlington, TX 76019, USA

Received 21 October 2016; accepted 28 October 2016

\textbf{Key Words}

Ca\textsuperscript{2+} channels; Store-operated Ca\textsuperscript{2+} entry; Cell proliferation; Migration; Apoptosis; Channel blockers; Cancer therapy

\textbf{Abstract}

The intracellular calcium ions (Ca\textsuperscript{2+}) act as second messenger to regulate gene transcription, cell proliferation, migration and death. Accumulating evidences have demonstrated that intracellular Ca\textsuperscript{2+} homeostasis is altered in cancer cells and the alteration is involved in tumor initiation, angiogenesis, progression and metastasis. Targeting derailed Ca\textsuperscript{2+} signaling for cancer therapy has become an emerging research area. This review summarizes some important Ca\textsuperscript{2+} channels, transporters and Ca\textsuperscript{2+}-ATPases, which have been reported to be altered in human cancer patients. It discusses the current research effort toward evaluation of the blockers, inhibitors or regulators for Ca\textsuperscript{2+} channels/transporters or Ca\textsuperscript{2+}-ATPase pumps as anti-cancer drugs. This review is also aimed to stimulate interest in, and support for research...
1. Introduction

Intracellular calcium ions (Ca\(^{2+}\)), the most abundant second messenger in human body, have a substantial diversity of roles in fundamental cellular physiology, including gene expression, cell cycle control, cell motility, autophagy and apoptosis\(^1\). Since the cytosol Ca\(^{2+}\) is maintained very low (~10\(^{-7}\) mol/L), a small fraction of Ca\(^{2+}\) either through release from intracellular organelles (~10\(^{-5}\) mol/L) or through influx from extracellular reservoir (~10\(^{-3}\) mol/L) can generate marked signals to activate downstream signaling cascade. Increase in Ca\(^{2+}\) levels are highly localized, such as the microdomains in the vicinity of inositol 1,4,5-trisphosphate receptor (IP\(_R\)) or store-operated Ca\(^{2+}\) entry (SOCE) channel\(^2\). Alternatively, local changes in intracellular Ca\(^{2+}\) can diffuse across the cell as a wave and elicit an effect at a distant site\(^3\). The prolonged intracellular elevation of Ca\(^{2+}\) can be toxic and triggers cell death\(^4\). Therefore, the Ca\(^{2+}\) signals in the form of waves, spikes or oscillations must be spatially-temporally tightly regulated\(^5\).

Among the three Ca\(^{2+}\) signal forms, intracellular Ca\(^{2+}\) oscillations provide efficient means to transmit intracellular biological information. For example, our previous study showed that intracellular Ca\(^{2+}\) oscillations provided essential proliferation signals for esophageal cancer cells\(^6\). In particular, the frequency, amplitude, and duration of these intracellular Ca\(^{2+}\) oscillations compose the specific Ca\(^{2+}\) codes for selective activation of transcription factors for gene transcription, cell proliferation and migration\(^7\). The decoding of the oscillatory form is achieved by intracellular downstream effectors, including calmodulin (CaM), nuclear factor of activated T-cells (NFAT), nuclear factor-xB (NF-xB), calmodulin-dependent protein kinase II (CaMKII) and calpain, which differ in their on- and off-rates for Ca\(^{2+}\) and subsequently activate different cellular processes\(^8-11\). Furthermore, different Ca\(^{2+}\) regulated kinases and enzymes often occupy distinct locations within the cell. Therefore, the size, kinetics and spatial profile of a cytoplasmic Ca\(^{2+}\) signal are all important in determining which Ca\(^{2+}\)-dependent response will be activated, when and for how long. Intracellular Ca\(^{2+}\) oscillations can reduce the effective Ca\(^{2+}\) threshold for signaling transduction, thereby increasing signal detection at low levels of stimulation\(^12\).

Disruption of normal Ca\(^{2+}\) signaling contributes to the development of malignant phenotypes\(^13\). In order to proliferate at high rates, to increase cell motility and invasion, to escape death, to fool immune-attack, or to have neovascularization, tumors remodel their Ca\(^{2+}\) signaling network. There has been an increasing awareness that tumorigenic pathways are associated with altered expression level or abnormal activation of Ca\(^{2+}\) channels, transporters or Ca\(^{2+}\)-ATPases\(^6,14-20\). Correction of these derailed Ca\(^{2+}\) signals could provide potential cancer therapies. In this review, we will summarize the Ca\(^{2+}\) channels, transporters and Ca\(^{2+}\)-ATPases, which are altered and play important roles in cancer biology. We will also discuss the current effort in this emerging research area toward evaluation of a certain numbers of Ca\(^{2+}\) channel blockers or regulators and Ca\(^{2+}\)-ATPase pump inhibitors as anti-cancer drugs.

© 2017 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

2. Altered Ca\(^{2+}\) channels/transporters in cancer

The intracellular Ca\(^{2+}\) homeostasis is governed by a network composed of various Ca\(^{2+}\) channels and transporters: (1) IP\(_R\) or ryanodine receptor (RyR) mediating Ca\(^{2+}\) release from endoplasmic/sarcoplasmic reticulum (ER/SR); (2) Ca\(^{2+}\)-ATPase pumping Ca\(^{2+}\) from cytosol back to ER/SR or extracellular space; (3) Ca\(^{2+}\) channels or transporters allowing Ca\(^{2+}\) influx across plasma membrane (PM) from extracellular Ca\(^{2+}\) reservoir, such as voltage-gated Ca\(^{2+}\) channel (VGCC), transient receptor potential channel (TRP), Ca\(^{2+}\) release-activated Ca\(^{2+}\) channel (CRAC), Na\(^{+}/Ca\(^{2+}\) exchanger (NCX) and purinergic receptor; (4) mitochondrial Ca\(^{2+}\) uniporter (MCU) regulating mitochondrial Ca\(^{2+}\) uptake (Fig. 1). It is beyond the scope of this brief review to cover all the Ca\(^{2+}\) channels, transporters or Ca\(^{2+}\)-ATPases for intracellular Ca\(^{2+}\) homeostasis; instead, we will focus on a few important ones, which have been reported to be dysregulated in cancer cells (Table 1).

![Figure 1 Important Ca\(^{2+}\) channels/transporters/pumps in cancer cells](image)

Research into the understanding of cellular mechanisms underlying the regulation of Ca\(^{2+}\) signaling in different cancer cells, and to search for novel therapies to cure these malignancies by targeting Ca\(^{2+}\) channels or transporters.

Figure 1 Important Ca\(^{2+}\) channels/transporters/pumps in cancer cells. The dynamic of intracellular Ca\(^{2+}\) is governed by a series of proteins: (1) IP\(_R\)s mediating Ca\(^{2+}\) release from endoplasmic reticulum (ER); (2) Ca\(^{2+}\)-ATPases pumping Ca\(^{2+}\) from cytosol to the ER or to extracellular space; (3) plasma membrane Ca\(^{2+}\) channels or transporters, such as VGCCs, TRPs, CRACs, NCXs and P2 receptors; (4) mitochondrial Ca\(^{2+}\) uniporter. The tightly regulated Ca\(^{2+}\) signals in the form of waves, spikes or oscillations can regulate a wide range of cellular events, including gene transcription, proliferation, migration and apoptosis. Targeting the dysregulated Ca\(^{2+}\) channels/transporters/pumps may provide a promising chemotherapy for cancer patients.
2.1. IP₃Rs — ER Ca²⁺ release channels

ER and SR are the major intracellular Ca²⁺ storage organelles in non-excitable and excitable cells, respectively. While RyRs are predominantly expressed in excitable cells, IP₃Rs are the main intracellular Ca²⁺ release channels in non-excitable cells, including many cancer cells. So far, three isoforms of IP₃R, i.e. IP₃R1, IP₃R2 and IP₃R3 have been identified, which display different affinity to IP₃ with similar but not identical functional properties²¹. The general domain structure of IP₃Rs includes the IP₃ binding site at the N-terminal region, the six transmembrane spanning domains at the C-terminal, a large number of cytoplasmic regulatory sites and protein-binding domains. Among these protein-binding domains, a significant one between amino acid 1390–1409 mediates the interaction with the BH₄ domain of anti-apoptotic protein Bcl-2. IP₃-R-mediated ER Ca²⁺ release participates in the overall intracellular Ca²⁺ signaling network and regulates fundamental cellular functions, such as cell proliferation and differentiation²². Moreover, recent studies have demonstrated that mitochondria and ER can form structural link. Together with other interacting proteins, such as BCL-2 and BAX/BAM, the IP₃R directly stimulates the mitochondrial Ca²⁺ uptake²³. Through this ER/mitochondrial crosstalk, IP₃Rs can further determine the cell fate by controlling the mitochondrial Ca²⁺ elevation and metabolism.

Altered IP₃R activity and/or the remodeling of IP₃-R-expression profile have been found in a number of cancers (Table 1). Compared with normal brain tissues, human glioblastoma samples present decreased IP₃R1 and increased IP₃R3. Kang et al.²⁴ demonstrated that caffeine could inhibit IP₃R₃-mediated Ca²⁺ release, thus reduced migration of cultured glioblastoma cells and greatly increased mean survival in a mouse xenograft model of glioblastoma. The upregulation of IP₃R₃ has been observed in gastric cancer cell lines established from malignant ascites, but not in a cell line established from primary tumor or normal gastric epithelial cells²⁵. In a clinical association study, Shibao et al.²⁶ examined whether gain of expression of IP₃-R isoforms is associated with development of colorectal cancer using colorectal carcinomas tissues surgically resected from over a hundred patients. They found that IP₃R1 and IP₃R₂ were expressed in both normal colorectal mucosa and colorectal cancer, while IP₃R₃ was only observed in colorectal cancer, especially in the advancing margins of tumors correlated with depth of invasion, lymph node metastasis, liver metastasis, and TNM stage. High expression of IP₃R₃ is associated with aggressiveness of colorectal carcinoma since it is related with decreased 5-year survival. A mutation in IP₃R₃ encoding gene ITTR3 was identified in genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma²⁷. Similarly like IP₃R1 and IP₃R₃, the dysregulation of IP₃R₂ was observed in chronic lymphocytic leukemia cells²⁸. The expression of IP₃R₂ is significantly upregulated, which in turn may enhance mitochondrial function and energy production to accommodate for the higher metabolic activity and the induced proliferation of leukemia cells. It is notable that the role of IP₃R₂ may be complicated. Ouyang et al., recently reported that IP₃R₂ mediated Ca²⁺ signaling is required to reinforce the developmentally important transcription factor TCF-1 for normal development and thymocyte neoplasia prevention. Mice without IP₃-Rs in thymocyte developed aggressive T-cell malignancies that resemble human T-cell acute lymphoblastic leukemia²⁹.

2.2. Ca²⁺-ATPases

The low cytosolic Ca²⁺ concentration is maintained by the Ca²⁺ transport system, i.e. Ca²⁺-ATPases. They rapidly pump cytosolic Ca²⁺ ions back into intracellular organelles, e.g. ER, or to extrude Ca²⁺ ions to extracellular space. These Ca²⁺-ATPases belong to the superfamilies of P-type ATPase (E1E2-type) and can be further divided into three subtypes according to their subcellular localizations: plasma membrane Ca²⁺-ATPase (PMCA), ER/SR Ca²⁺-ATPase (SERCA), golgi/golgi-derived vesicles secretory pathway Ca²⁺-ATPase (SPCA). Each subtype contains multiple isoforms and splice variants, which present tissue-specific expression, regulation, and kinetic characteristics. As such, the Ca²⁺-ATPases contribute to a highly complex and fine-tuned intracellular Ca²⁺ signaling network³⁰.

Among the Ca²⁺-ATPase family members, SERCA is the best characterized one. SERCA is responsible for replenishing ER Ca²⁺ stores, maintaining protein proper folding/maturatation whereas dysregulated SERCA results in depleted or overloaded ER lumen Ca²⁺ stores, increased ER stress, dysregulated chaperones and synthesis of lipids. Mutations and altered expression levels of SERCA isoforms have been identified in various cancers, such as cancers of colon, gastric, lung, myeloid leukemia and choroid plexus tumors³¹ (Table 1). Overexpression of SERCA₂ was found in colorectal cancer cells, which may drive proliferation and migration³². On the other hand, SERCA₃ was reported to have progressively lost during multistage process of colon tumorigenesis after initial increased expression during cell differentiation³³. In B lymphocytes, SERCA₃ was also found to be downregulated after the infection of Epstein Barr virus, a human gamma herpes-virus involved in various malignancies including Burkitt’s and other lymphomas³⁴.

Altered expression of SPCA isoforms occurs in various types of cancer including breast, colon and prostate³⁰. Clinical data showed that SPCA₁ is highly expressed in basal-like breast cancers and has a low expression in the luminal subtypes³⁵. Feng et al.³⁶ identified up-regulation of SPCA₂ in breast cancer-derived cells and human breast tumors. Knockdown of SPCA₂ resulted in attenuated growth as well as decreased colony formation of MCF7 cells in soft agar and reduced tumor formation in xenografted mice. Furthermore, overexpression of SPCA₂ is able to confer increased proliferation and colony formation capability in soft agar assay in MCF10A cells, a nonmalignant mammary epithelial cell line. On the other hand, knockdown of SPCA₂ and low Ca²⁺-conditions are able to decrease activity of ERK1/2 pathway, which may result in decreased proliferation in breast cancer cells. SPCA₂ appears to have the unique ability to elicit store-independent Ca²⁺ entry, i.e. a constitutive Ca²⁺ entry pathway, which in turn promotes proliferative potential of cancer cells³⁶.

The association between altered PMCA and cancer has been reported in a few studies as well (Table 1). PMCA₂, the isoform predominantly expressed in mammary epithelia for the apical efflux of Ca²⁺ during lactation, is highly expressed in certain numbers of breast cancer cell lines³⁷. In these breast cancer cell lines, PMCA₂ is constitutively expressed at levels as over 100-fold high as in non-tumorigenic lines. As such, PMCA₂ can keep low cytosolic Ca²⁺ levels and bypass apoptosis by preventing increased uptake of Ca²⁺ into mitochondria. On the contrary, PMCA₄ and PMCA₁ are down-regulated in colon or oral squamous cell carcinoma, respectively, which increase cytosolic Ca²⁺ to enhance cell proliferation³⁸-³⁹. These observations suggest
that different cancer cells may develop different means to fulfill special needs for intracellular Ca\(^{2+}\) signaling, and either up or down regulation of Ca\(^{2+}\)-ATPases is used to facilitate a particular type of cancer cells to escape from normal cellular control and to promote tumorigenesis.

2.3. Plasma membrane Ca\(^{2+}\) channels

2.3.1. Voltage-gated Ca\(^{2+}\) channels

VGCCs (also known as Ca\(_{\text{a}}\) family) mediate a fast Ca\(^{2+}\) influx in response to membrane depolarization. There are 6 subfamilies of VGCCs, i.e., L-, N-, P-, Q-, R- and T-type. The Ca\(_{\text{a}}\)1 conducts L-type Ca\(^{2+}\) currents, initiating muscle contraction and endocrine secretion; the Ca\(_{\text{a}}\)2 conducts N-, P/Q- and R-type Ca\(^{2+}\) currents, initiating rapid synaptic transmission; the Ca\(_{\text{a}}\)3 conducts T-type Ca\(^{2+}\) currents, which are characterized by more rapid activation and inactivation by membrane depolarization\(^{10}\).

A recent meta-analysis of microarray datasets revealed VGCCs mRNA gene profile of different types of cancers.\(^{41}\) L-type Ca\(^{2+}\) channels are implicated in the development and progression of several tumors, such as significantly up-regulated in colon and esophageal cancers. Novel splice variants of T-type Ca\(^{2+}\) channel are commonly found in human glioma, breast, ovarian, prostate colon and esophageal cancer cells. For example, Ca\(_{\text{a}}\)3.1a transcripts predominate in the normal adult brain and Ca\(_{\text{a}}\)3.1b is mostly fetal-specific; but human glioma and glioma cell lines contain Ca\(_{\text{a}}\)3.1bc as predominant splice and Ca\(_{\text{a}}\)3.1ac as a novel splice variant, which is absent in normal brain or fetal astrocytes.\(^{62-64}\).

2.3.2. TRP channels

The super family of TRP channels include more than 30 members, which can be further divided into 7 subgroups, i.e., TRPA (ankyrin), TRPC (canonical), TRPM (melastatin), TRPML (mucolipin), TRPP (polycystic), TRPN (no mechanoreceptor potential C), and TRPV (vanilloid).\(^{47}\) Mammalian TRP proteins form homo- or hetero tetrameric non-selective Ca\(^{2+}\)-permeable cation channels, which can be activated and regulated by a wide variety of stimuli, such as Ca\(^{2+}\), temperature, pH, ROS, chemical and mechanical stress. As such, they are perfect candidates for cellular sensors and are believed to actively participate in the tumor–microenvironment cross-talk.\(^{48}\)

As summarized in Table 1, a large number of TRP members present altered expression and/or channel activity in a variety of cancers. For example, the presence of the TRPC, TRPM, and TRPV subfamilies correlates with malignant growth and cancer progression.\(^{8-58}\) TRPM7, 8 and TRPV2, 6 are associated with the prostate cancer progression and TRPC6 as a novel therapeutic target for esophageal carcinoma.\(^{19,54-58}\) In breast cancer, TRPC1, TRPC6, TRPM7, TRPM8, and TRPV6 are overexpressed, and their expression profiles are associated with pathologic parameters, suggesting their use as prognostic markers.\(^{37,59}\) The expression profile of TRPM7/8 depends on both invasive and hormonal status: in non-invasive estrogen-positive cells, TRPM7 is highly expressed and mediates Ca\(^{2+}\) influx, which results in proliferation and poor differentiation;\(^{40}\) on the other hand, TRPM8 is highly expressed in non-invasive well-differentiated estrogen-positive breast cancer, and may serve as a good prognostic marker for this type cancer;\(^{63}\) in aggressive estrogen-negative cancers, they regulate cell migration through an interaction with cytoskeleton proteins.\(^{42,65}\) Besides mentioned above, there are still some other TRP family proteins involved and contributed to cancer development, which were summarized in Table 1. Therefore the expression of TRP channels has been proposed as a tool for diagnosis or predicting prognosis in several cancers, and targeting TRP channels has been suggested as a novel therapeutic strategy.\(^{48}\)

2.3.3. Orai and STIM

Another type of Ca\(^{2+}\) influx channels, including CRAC, arachidonate-regulated Ca\(^{2+}\) entry channel and SOCE channel has been demonstrated to heavily involve in cancer biology (Table 1). The activation of canonical SOCE pathway contains several steps, i.e. reduction or depletion of ER Ca\(^{2+}\) stores, translocation of ER-localized Ca\(^{2+}\) sensor STIM1 to ER-plasma membrane junctions, aggregation and conformational changes of cell surface Orai channels, and final Ca\(^{2+}\) influx. To date, three isoforms of Orai (Orai1, Orai2 and Orai3) and two isoforms of STIM (STIM1 and STIM2) have been identified in mammals.\(^{60}\)

Among these SOCE machinery proteins, Orai1 and STIM1 are the two well characterized. Yang et al.\(^{64}\) first reported that STIM1 and Orai1 played a crucial role in breast cancer migration and metastasis. We also showed that Orai1 expression was elevated in tumor tissues compared with normal adjacent tissues removed from patients suffering from esophageal squamous cell carcinoma; more importantly, the elevated Orai1 expression was associated with poor prognosis. Inhibition of Orai1 channel either by pharmacological compounds or knocking-down of Orai1 expression could block cancer cell proliferation and migration in vitro and tumor growth in vivo.\(^{65}\) Later, Orai1 and STIM1 were also found to promote cell proliferation, migration, invasion and apoptotic resistance in glioblastoma, pancreatic adenocarcinoma, prostate cancer, hepatocellular carcinoma,\(^{66}\) and clear cell renal cell carcinoma.\(^{70}\)

Interestingly, STIM1 and STIM2 are involved in the anti-tumor activity of cytotoxic T cells, i.e. secretion of cytokines, such as TNFα, IL-2 and IFNγ, which induce apoptosis of cancer cells.\(^{71,72}\) Studies about roles of STIM2 in cancer still unconsolidated. A few reports demonstrated STIM2, as a proliferation suppressor, contributed to apoptotic resistance in colorectal cancer cells; while others revealed STIM2-mediated SOCE promote melanoma cells proliferation.\(^{73,74}\) This may indicate that multifaceted STIM2 exert specific functions in different types of cancer.

Compared with Orai1, much less is known about Orai2 and Orai3 in malignant diseases. Except up-regulated in non-small cell lung cancer (NSCLC) and contributed to cell proliferation and tumor grades, Orai3 is also overexpressed in breast cancer tissues, cell lines MCF-7 and T47D as respectively compared to adjacent normal tissues and non-cancerous cell line MCF-10A.\(^{75,76}\) Motiani et al.\(^{77,78}\) showed that abnormal SOCE was mediated by Orai3 in estrogen-receptor-positive breast cancer lines and this increased the proto-oncogenes NFAT transcriptional activity through MAP kinase pathway. Orai3 and Orai1 form arachidonate-regulated Ca\(^{2+}\) entry channel and their ratio represents an oncogenic switch, which facilitates proliferation and apoptotic resistance in prostate cancer.\(^{68}\) More detailed discussion on recent advances in SOCE and its contribution to cancer can be found in our review article published elsewhere.\(^{79}\)

2.3.4. Purinergic receptors

Purinergic signaling receptors for extracellular nucleotides (P1 and P2 receptors) are widely expressed by mammalian cells. The P2 receptors are divided into P2X and P2Y groups and each group contains several members with distinct ion selectivity and regulatory properties. Numerous studies have demonstrated that P2 receptors involve in cancer cells and are expressed to a very high level in some cases, such as P2X3, P2X5, P2X7 and P2Y2 and...
P2Y4\textsuperscript{42,80–83} (Table 1). In terms of clinical evaluation, P2X3 receptor overexpression was reported to be associated with poor recurrence-free survival in hepatocellular carcinoma patients\textsuperscript{84}.

2.4. Mitochondrial Ca\textsuperscript{2+} uniporter

Mitochondria are capable for rapid Ca\textsuperscript{2+} uptake and thus actively shape the overall intracellular Ca\textsuperscript{2+} signaling. Their Ca\textsuperscript{2+} uptakes are mediated largely by mitochondrial Ca\textsuperscript{2+} uniporter (MCU) and regulated by a gate keeper protein mitochondrial Ca\textsuperscript{2+} uptake 1 (MICU1)\textsuperscript{85}. The accumulated mitochondrial Ca\textsuperscript{2+} ions are quickly pumped back to cytosol by mitochondrial NCX and mitochondrial H\textsuperscript{+}/Ca\textsuperscript{2+} exchangers (HCX)\textsuperscript{86}. A wide variety of studies reported the involvement of these mitochondrial Ca\textsuperscript{2+} handling proteins in cancer cell metabolism, apoptosis and proliferation. Overexpression of MCU is reported in the clinical estrogen receptor negative and basal-like breast cancer samples\textsuperscript{87}. However, down-regulation of MCU in colon and prostate-derived cancers has been shown to promote increased proliferation and bestows resistance to cell death stimuli through diminished mitochondrial Ca\textsuperscript{2+} levels\textsuperscript{88}. Down-regulation of MICU1, which results in mitochondrial Ca\textsuperscript{2+} overload, did not alter proliferation in HeLa cells; however, it triggers excessive mROS generation and significantly enhances sensitivity to apoptotic stress\textsuperscript{85,89}.

### Table 1 | Altered Ca\textsuperscript{2+} channels/transporters/pumps in cancers.

| Channel/transporter | Cancer type | Changes | Ref. |
|---------------------|-------------|---------|------|
| IP\textsubscript{3}R | IP\textsubscript{3}R1 | Glioma | Decreased | 24 |
|                     | IP\textsubscript{3}R2 | Lymphocytic leukemia | Increased | 28 |
|                     | IP\textsubscript{3}R3 | Glioma, gastric, colon, head and neck cancer | Increased/Mutation | 24–27 |
| Ca\textsuperscript{2+}-ATPase | SERCA2 | Colon cancer | Increased | 32 |
|                     | SERCA3 | Gastric, lung, choroid plexus tumors, and in myeloid leukemia | Decreased | 31 |
|                     | SPCA1 | Breast cancer | Increased | 35 |
|                     | SPCA2 | Breast cancer | Increased | 36 |
|                     | PMCA1 | Oral cancer | Decreased | 39 |
|                     | PMCA2 | Breast cancer | mRNA elevated | 37 |
|                     | PMCA4 | Colon cancer | Decreased | 38 |
| VGCC | Ca\textsubscript{1,2} | Colon and esophageal cancer | Increased | 42 |
|       | Ca\textsubscript{2,3} | Glioma | Increased | 42 |
|       | Ca\textsubscript{3,1} | Glioma | Increased | 46 |
|       | Ca\textsubscript{3,2} | Prostate, ovarian, glioma, breast, esophageal, hepatoma, melanoma, and colon cancer | Increased | 42–45 |
| TRP | TRPC1 | Breast cancer | Increased | 49 |
|       | TRPC3 | Ovarian and breast cancer | Increased | 50, 51 |
|       | TRPC6 | Esophageal, glioma and breast cancer | Increased | 51, 57, 90 |
|       | TRPM1 | Melanoma | Decreased | 91 |
|       | TRPM7 | Pancreatic and breast cancer | Increased | 60, 92 |
|       | TRPM8 | Pancreatic, prostate, bladder, breast, melanoma, colon and lung cancer | Increased | 58,92, 93 |
|       | TRPV1 | Bladder and prostate cancer | Decreased/Increased | 94, 95 |
|       | TRPV2 | Bladder, prostate cancer and hepatocarcinoma | Decreased/Increased | 96 |
|       | TRPV4 | Non-melanoma skin cancer, tumor endothelial cell derived prostate and breast cancer | Decreased | 97–99 |
|       | TRPV6 | Breast, prostate, lung, thyroid, colon and ovarian cancer | Increased | 100–103 |
| Orai & STIM | Orai1 | Pancreatic adenocarcinoma, glioma, melanoma, breast, esophageal, renal, and NSCLC | Increased/Constitutive activated | 6, 36, 65, 66, 74, 104–106 |
|       | Orai3 | Breast, prostate and lung cancer | Increased | 68, 76, 78 |
|       | STIM1 | Hepatoma, melanoma, cervical, colorectal cancer, breast and pancreatic adenocarcinoma | Increased | 66, 69, 104, 107–109 |
|       | STIM2 | Breast, colorectal cancer and melanoma | Increased/Decreased | 73,74,109, 110 |
| Purinergic receptor | P2X3 | Hepatoma | Increased | 84 |
|       | P2X5 | Melanoma, colorectal, brain, breast and renal cancer | Increased | 42 |
|       | P2X7 | Neuroblastoma, melanoma, leukemia, breast, prostate, papillary thyroid, pancreatic, colon, renal, cervical and B chronic cancer | Increased | 42,80 |
|       | P2Y2 | Highly metastatic breast cancer, hepatoma and colon cancer | Increased | 81–83 |
|       | P2Y4 | Colon cancer | Increased | 83 |
| MCU | Breast, colon and prostate cancer | Decreased/Increased | 87,88 |
3. Drugs targeting Ca$^{2+}$-channels/transporters/pumps for cancer treatment

The complexity of widespread Ca$^{2+}$-channels/transporters/pumps with the diverse activation process, offers an abundance of potential targets for pharmacological regulation and cancer chemotherapy. Progress in understanding of the intracellular Ca$^{2+}$ signaling network, especially the channels/transporters/pumps structure, has significantly advanced the field of drug design and development with particular focus on potentials and specific selectivity inhibitor or regulator. In this section, we attempt to summarize the known compounds or antibodies targeting these above mentioned cancer-involved Ca$^{2+}$ channels/transporters/pumps, which have been studied in pre-clinical research or even in clinical trials (Table 2). A certain number of these compounds have been demonstrated with promising ability to be used in cancer therapy.

3.1. Ca$^{2+}$-ATPase inhibitors

The sustained high cytoplasm Ca$^{2+}$ is toxic for cells by activating cell death signaling. Ca$^{2+}$-ATPases can be easily targeted by shutting-down of these pumps to generate such toxic cytosolic Ca$^{2+}$ concentrations for either apoptosis or necrosis. A PMCA selective inhibitor [PT(O,α-acac)(γ-acac)(DMS)] is used to rapidly induce apoptosis in MCF-7 cells, which may induce ROS in addition to cytosol Ca$^{2+}$ elevation. Our earlier work showed that the depletion of ER Ca$^{2+}$ stores itself is sufficient to cause ER stress and to induce programmed cell death pathways. A selective inhibitor of SERCA pump, thapsigargin (TG), is used to inhibit Ca$^{2+}$ uptake into ER and deplete ER Ca$^{2+}$ stores. The application of TG as chemotherapeutic agent has been extensively studied in prostate cancer and other cancers. However, a barrier preventing the direct usage of TG as clinical effective drug is its non-selectivity since TG will destroy intracellular Ca$^{2+}$ homeostasis not only in cancer cells but also in normal cells. Thus the research effort on development of TG as chemotherapy drug has been focused on tumor targeting. One successful example is G202, in which an analogue to TG is conjugated to prostate-specific membrane antigen (PSMA) targeting peptide. PSMA is a type II membrane carboxypeptidase and is overexpressed in prostate cancer cells and most tumor endothelial cells, but not in normal vasculature or normal tissue epithelium. As a prodrug, G202 itself is non-toxic since it cannot enter the cell due to its size. Once it reaches tumor, it binds with PSMA and subsequently PSMA can cleave the peptide and release active cytotoxic analog of TG. G202, later termed as mipsagargin, significantly inhibits tumor progression including prostate, breast and bladder cancers, while presenting minimally toxicity to the host animals. G202 has showed promising results in several pre-clinical studies and is currently in phase II clinical trial for prostate cancer and progressive glioblastoma.

3.2. Voltage-gated Ca$^{2+}$ channel inhibitors

The first well-studied family of compounds targeting Ca$^{2+}$ signaling are the inhibitors for VGCCs, which are widely used in the cardiovascular or nervous system diseases. As accumulating evidences reveal the important roles of VGCCs in a number of cancers, many investigators have launched the studies to repurpose the FDA approved drugs targeting VGCCs for cancer treatment. In fact, as early as in 1990s, some structurally unrelated L-type VGCCs antagonists were tested for their potent inhibitory effects on breast tumor progression. The dihydropyridine Ca$^{2+}$ channel blocker, amiodipine, was found to inhibit the growth of human epidermoid carcinoma A431 cells both in vitro and in vivo, via arresting cell cycle at G1 phase and reducing phosphorylation of retinoblastoma protein, expression levels of cyclin D1 and cyclin dependent kinase 4. Another interesting case is mibebradil, a T- and L-type Ca$^{2+}$ channel blocker used for anti-hypertensive. It was later voluntarily withdrawn from market due to its side effect of inhibiting cytochrome P450 enzymes 2D6, 3A4 and p-glycoprotein. However, mibebradil was shown to be able efficiently to reduce tumor size, to improve the survival rate in glioma animal model as well as in a patient derived pancreas xenograft animal model. Therefore, mibebradil was repurposed for pancreatic cancer and high-grade glioma therapy. FDA swiftly approved mibebradil as an orphan drug for pancreatic cancer treatment in 2008 and its use for glioma treatment has also been moved into clinical trial. Moreover, a mibebradil derived novel compound, NNC-55-0396, was developed to selectively target Ca$^{2+}$ channel and exhibits less inhibitory effect on cytochrome P450 3A4. This new derived mibebradil compound appears to be a promising chemotherapy drug for that it is able to effectively inhibit angiogenesis in cancer cell lines but with minimal off-target effect.

3.3. TRP channel regulators

The imidazole compound SKF-96365 and related antimycotic compounds including econazole, miconazole, and clotrimazole can inhibit CRACs and some TRP channels. While SKF-96365 was firstly described to block receptor-mediated Ca$^{2+}$ entry in human platelets, neutrophils and endothelial cells, it later was used to inhibit ovarian cancerous cell growth and tumorigenesis via reducing activities of different subtypes of TRPCs. Treatment of SKF-96365 was reported to enhance radio-sensitization in glioblastoma, which contain high expressing levels of TRPC6 channels. In addition, SKF-96365 can also cause cell cycle arrest at S and G2 phases in glioblastoma cells via enhancing reverse mode of the NCX1, independent of TRPCs.

Using a structure-based design, a synthetic compound TH-1177 mimicking dihydropyridines was developed as a TRPV channel blocker. It inhibits prostate cancer cell proliferation in vitro and in vivo. However, there is one issue preventing TH-1177 from further clinical application. It preferentially inhibits TRPV5 but less effective for TRPV6 channel; whereas TRPV6 is the most abundantCa$^{2+}$ entry channel in prostate cancer cells with its expression level as high as 45-fold more than TRPV5. Thus, TH-1177 was further modified to possess high selectivity for TRPV6 and this new agent has been demonstrated significantly improved inhibitory effects on cell proliferation in prostate and breast cancer.

GSK1016790A is a selective TRPV4 channel agonist developed recently. It is at least 300-fold more potent than the commonly used TRPV4 activator 4α-PDD. TRPV4 is able to regulate tumor angiogenesis and vessel maturation, thus GSK1016790A has been proposed to be used together with other anticancer drugs, such as cisplatin, to improve tumor penetration for more effective cancer therapy. By mimicking the C-terminus of soricidin, two TRPV6 inhibitors, the SOR-C13 and SOR-C27 bind TRPV6 with high affinity in ovarian cancer cells. SOR-C13 is currently in phase I clinical trial for advanced cancers, in which...
| Channel/Transporter | Compound | Mechanism       | Cancer                                           | Ref.     |
|---------------------|----------|-----------------|-------------------------------------------------|----------|
| Ca\(^{2+}\)-ATPase  | SERCA    | Inhibitor       | Prostate, hepatoma, colon, cervical, breast cancer and nasopharyngeal | 111–115  |
|                     | SERCA2   | Inhibitor       | Colon cancer                                    | 116      |
|                     | PMCA     | Inhibitor       | Breast cancer                                   | 117      |
| VGCC                | T-type   | Blocker         | Hepatoma, lung pancreatic cancer, epidermoid carcinoma and glioma | 118–121  |
|                     | T-type   | Increase protein expression | Prostate cancer | 122 |
| TRP                 | TRPA1    | Inhibitor       | –                                                | 123      |
|                     |          | Activator       | Gliona, melanoma, uterine, lung and breast cancer | 124      |
| TRPC                | 20-GPPD  | Activator       | Colon cancer                                    | 125      |
| TRPC                | SKP96365, M804 | Blocker     | Gliona                                           | 126,127  |
| TRPC1               | EVP4593  | Inhibitor       | Neuroblastaoma                                  | 128      |
| TRPC4/5             | (−)-Englerin A | Activator | Renal and colon cancer                          | 129,130  |
| TRPC4/5             | M804 analog, ML204 | Inhibitor | –                                                | 126,131  |
| TRPC3/6             | GSK2332255B, GSK2833503A | Inhibitor | –                                                | 132      |
| TRPC6               | GaQ\(_1\) | Induce protein expression | Breast, lung, osteosarcoma and hepatoma cancer | 133      |
| TRPV                | CPZ      | Inhibitor       | OSCC                                            | 134      |
| TRPV1               | CBD, Capsaicin | Agonist     | Cancer of colon, renal carcinoma.                | 135–138  |
| TRPV2               | 2-APB, cannabinoid, lysophospholipid and probenecid | Agonist | Glioblastoma, bladder cancer                     | 96,139,140 |
| TRPV4               | Ruthenium red, TEA, TRIM, 4-aminopyridine, SKP96365 and tranilast | Antagonist | Breast cancer                                   | 96,139,141 |
|                     | GSK1016790A | Agonist       | Prostate cancer                                 | 98,142   |
|                     | GSK2193874, RN-9893, BTP2 | Inhibitor | –                                                | 143–145  |
| TRPM8               | CBG, M8-B | Inhibitor       | Lymphoma, lung, breast, prostate and skin pancreatic, | 146–148  |
|                     | D-3263   | Agonist         | Various advanced cancer                         | 93,149   |
| TRPML               | ML-SA1   | Agonist         | –                                                | 150      |
| TRPML1              | MK6-83   | Agonist         | –                                                | 151      |
| TRPV6               | TH-1177, Soricidin, SOR-C13 and SOR-C27 | Inhibitor | Ovarian, prostate and brain cancer               | 152–154  |
| Orai                | CRAC     | Inhibitor       | Hepatoma, lung, bladder, kidney, NSCLC, glioma and leukemia | 155–159  |
| STIM1               | ML-9     | Translocation inhibitor | Prostate Cancer | 160,161 |
| Orai1-STIM1         | SKP96365 | Inhibitor       | Esophageal, breast and colon cancer             | 6,64,108 |
| Orai1               | La\(^{3+}\), Gd\(^{3+}\), AnCoA4, SB01990, SBP06836, SBM0293, RHO1882, GSK-5503A, GSK-7975A, mAbs | Inhibitor | Lung cancer and glioma                          | 65,162–166 |
| −                   | 2-APB and its analogues, DPB-162AE and DPB-163AE | Inhibitor/Activator | Colon cancer and glioma                          | 65,108,167,168 |
| −                   | RO2959   | Inhibitor       | –                                                | 169      |
TRPV6 channels are normally overexpressed\textsuperscript{153}. Another compound in phase I clinical trial with similar mechanism is D-3263. It is an activator for TRPM8 and induces cancer cell apoptosis, which is proposed to be used for patients with solid tumors\textsuperscript{93}.

Capsaicin, a well-known activator for TRPV1, was shown to induce apoptosis by its action on TRPV6 but independent on TRPV1, followed by activation of calpains in human small cell lung cancer cells (SCLC) in vitro\textsuperscript{101}. TRPV antagonist capsazepine (CPZ) was demonstrated to effectively inhibit oral squamous cell carcinoma cells (OSCC) growth in vivo\textsuperscript{134}. Subcutaneous injection of either capsaicin or CPZ significantly suppresses PC-3 tumor growth by inducing apoptosis of tumor cells in vivo, suggesting they are promising chemotherapy drugs\textsuperscript{195}. Sesquiterpene (\textsuperscript{1/C})-englerin A is a selective and potent activator for TRPC4 and TRPC5, which results in massive Ca\textsuperscript{2+} influx followed by cell death and retarded tumor cell growth\textsuperscript{129,130}. However, its severe lethal side effect must be resolved before it can be considered as a potential therapeutic agent. The natural compound, 20-GPPD, a metabolite of ginseng saponin, induces TRPC-mediated Ca\textsuperscript{2+} influx and apoptosis in CT-26 cells and reduces tumor mass by 75\% in vivo although the exact molecular target remains unknown\textsuperscript{125}. Some cannabinoid compounds, in particular cannabidiol (CBD), stimulate TRPV1 while the non-psychotropic cannabigerol (CBG) is an antagonist of TRPM8\textsuperscript{146}. CBD displayed anti-invasive action in human lung carcinoma A549 cells, dependent on the effect of CBD cannabinoid receptor and TRPV1\textsuperscript{196}.

3.4. Orai inhibitors

Among many known compounds targeting CRAC or SOCE, the Orai channel blockers are particularly well studied. Because CRAC channels present highly selective Ca\textsuperscript{2+} conductance, they are subject to blockage by the trivalent ions La\textsuperscript{3+} and Gd\textsuperscript{3+}. Both La\textsuperscript{3+} and Gd\textsuperscript{3+} can directly block CRAC pore formed by the I–II loop region of Orai1. However, this effect is not specific for CRAC, as La\textsuperscript{3+} and Gd\textsuperscript{3+} also block other Ca\textsuperscript{2+} channels as well, such as Ca_{\text{SM}} channel, TRP channel and PMCA\textsuperscript{162,163,197}.

The first Orai1 inhibitor used in cancer study is SKF-96365. Yang et al.\textsuperscript{64}, demonstrated that SKF-96365 can inhibit breast cancer cell migration in vitro and reduce tumor growth and metastasis in vivo. We also showed that SKF-96365 inhibited Orai1-mediated SOCE and intracellular Ca\textsuperscript{2+} oscillations in esophageal cancer cells and resulted in significant retarded tumor growth in nude mice\textsuperscript{6}.

Another commonly used SOCE inhibitor is 2-APB, which was initially identified as a noncompetitive antagonist of IP\textsubscript{3}R (at rather high concentration ~100 μmol/L)\textsuperscript{185}. The effects of 2-APB on SOCE are multifaceted. On one hand, 2-APB inhibits Orai1 current without interrupting STIM1 and Orai1 interaction\textsuperscript{198}; on the other hand, it can directly activate Orai3 channel independent on store depletion or STIM1\textsuperscript{159,200}. There is also a dose-dependent bimodal effect of 2-APB on SOCE, with strong enhancement at low doses (<5 μmol/L) and transient enhancement followed by inhibition at high concentrations (>20 μmol/L)\textsuperscript{167,201}. Although several studies demonstrated that 2-APB effectively inhibit cancer cell proliferation and tumor progression, the non-selective and multiple-target nature renders 2-APB unsuitable for chemotherapy\textsuperscript{132,108}. Much effort has been devoted to develop 2-APB derived compounds to overcome the obstacle. For example, DPB-162AE...
and DPB-163AE are constructed as dimers of 2-APB. They are over 100-fold more potent than 2-APB on SOCE inhibition, without affecting IP3R function at such concentrations.[168] Nevertheless, there will be a long journey before such compounds can be developed as effective chemotherapeutic drug.

Another line of research is screening of small-molecule compounds that bound to Orai1 and/or STIM1 in a microarray system containing minimal functional domains of STIM1 and Orai1. Some novel STIM–Orai inhibitors have been identified using this high-throughput screen approach, such as AnCoA4. AnCoA4 inhibits CRACs and attenuates T-cell activation both in vitro and in vivo. It reduces the recruitment of Orai1 into puncta and also inhibits the activity of the constitutively active Orai1 V102C channels, independent on STIM1.[166]

ML-9 is an inhibitor for myosin light-chain kinase (MLCK) and appears to be able to disperse STIM1 puncta, thus to inhibit SOCE. Although its target and mechanism of action are unclear, ML-9 is the only known inhibitor so far to inhibit STIM1 through interference with STIM1 translocation.[160] Later, ML-9 alone was proved to effectively induce prostate cancer cell death associated with autophagy in a concentration and Ca2+ dependent manner. Furthermore, combination of ML-9 and some other existing anticancer drugs, such as docetaxel, significantly promotes cancer cell death, suggesting ML-9 as a promising adjuvant drug for chemotherapy.[161]

RO2959 is a novel, potent and selective SOCE inhibitor (IC50 ~40 nmol/L). It inhibits a wide range of Ca2+ dependent cellular functions including gene expression, cytokine production, and proliferation in T cells. To achieve the IC50 values at nmol/L level, it requires pre-incubation of cells for more than 30 min, which suggests that RO2959 may act on Orai1 channels indirectly[169]. The effect of RO2959 in cancer and molecular basis of drug action, including whether it affects the function and choreography of STIM1, are still unclear.

Another class of potent CRAC inhibitor is designed targeting the Ca2+ selectivity filter of Orai channel. In particular, E106 accounts for Ca2+ selectivity in Orai1 and can be blocked by extracellular proton.[202] This class of inhibitor includes SB01990, SPB6836, KM06293 and RH01882, which all present the capability to alter the pore geometry of Orai1 and diminishes SOCE.[164]

Two pyrazole derivatives GSK-5503A and GSK-7975A slowly inhibit Orai1- and Orai3-mediated SOCE currents without affecting STIM1–Orai1 coupling. It takes a few minutes for the two compounds to have effects, suggesting that the mechanism is likely other than through the CRAC channel activation process.[165]

The IC50 is increased 10-fold in the Orai1E106D and in 2-APB compounds targeting NCX, such as OSW-1, showed apoptosis-mediated Ca2+ overload in leukemia.[169] The Pyr analogs, including Pyr2, 3, 6 and 10, show different selectivity on TRPC3 and Orai3/STIM1-mediated Ca2+ entry. Pyr10 is potent and selective for TRPC3-mediated responses (18-fold), and Pyr6 prefers Orai1/STIM1, while Pyr3 equally blocked the two channels[205]. The best-studied member of this group is Pyr2 (also known as BTP2 or YM-58483), a potent inhibitor for both CRAC and TRPC-mediated Ca2+ entry[217]. However, it also proposed that a key mechanism of BTP2 inhibition of Ca2+ influx and cytokine release might be related to its ability to depolarize the cell membrane via TRPM4 activation, thereby reducing the driving force for Ca2+ entry[206].

Synta 66 selectively inhibits ICrAC in RBL-1 cells, which is structurally similar to BTP2 but contains a biphenyl group rather than the pyrazole ring in BTP2[207]. Compared with BTP2 and the GSK compounds, the speed of inhibition by Synta 66 is rather slow. It requires pre-incubation with cells for more than 1 h and its effect is poorly reversible. These data suggest that the pore blocking mechanism is unlikely the case for Synta66. Moreover, Synta66 has no effect on STIM1 puncta formation, suggesting that it does not inhibit the early steps of STIM1 activation and translocation to junctional ER–PM sites.[208] CM2489 and CM3457 are another two promising inhibitors for SOCE, demonstrated in lymphocytes and T cell-derived cytokine production.[209] CM2489 has completed phase I clinical trials for the treatment of moderate-to-severe plaque psoriasis. This is the first CRAC channel inhibitor to be tested on humans and represents a promising lead for the development of novel therapeutics for human diseases, including cancers.

Recombinant Orai1 monoclonal antibodies (mAbs) exhibit strong and specific binding against Orai1 at amino acid residues 210–217 in the second extracellular loop. These mAbs, especially 2C1.1, inhibit ICrAC in Orai1 high expressed Jurkat T cells as well as HEK293.[170] Functional assays indicate that these mAbs strongly inhibited NFAT-dependent gene transcription in Jurkat cells or TG- and ionomycin-induced cytokine secretion from human T cells. Taking a similar approach, another specific anti-Orai1 mAb targeting the second extracellular loop, inhibits the proliferation of T cells and cytokine production both in vitro and in vivo. Further mechanistic studies suggested that mAb-targeted Orai1 proteins are internalized, which resulting in loss of functional SOCE activity.[211]. Although the anti-Orai1 mAbs-based potential therapy is limited in immune diseases, it raises high hope of similar application for cancer treatment.

### 3.5. Miscellaneous

Many regulators targeting Ca2+ channels/transporters/pumps other than the above mentioned, have been used in various areas, such as immune suppression, anti-hypertension and anti-cancer. Xestospongin B as a specific IP3R inhibitor has been demonstrated to reduce proliferation and colony formation ability, while induce necrotic death, specifically in tumorigenic breast cells, compared with non-tumorigenic cell lines.[172] Caffeine, a RyR agonist, can induce apoptosis in prostate cancer cells, while another agonist 4-chloro-m-cresol can inhibit the breast cancer cell growth[173]. Several compounds targeting NCX, such as OSW-1, showed apoptosis-induce function by causing mitochondrial Ca2+ overload in leukemia[174]. Brilliant blue G, a P2X7 antagonist, exhibits inhibitory effect on glioma growth. Emodin, a P2X non-specific inhibitor, reduces P2X7-mediated cancer cell migration. A number of P2X7 receptor regulators, such as antagonist A-438079 and A-74003 are mainly studied in pain relief. Since the P2 receptors play important roles in a certain number of cancers, it is reasonable to believe these antagonists may be potential effective anti-cancer drugs as well[172]. If that holds true, these compounds could exert dual functions as both chemotherapeutic agents and pain killer.

### 4. Conclusion and future directions

It is becoming evident that Ca2+ channels/transporters/pumps are involved in a wide range of cancers. Dysregulated Ca2+ homeostasis may play a role more like a “driver” than a “passenger” in carcinogenesis or tumorigenesis. As summarized in this review, this relatively new field has already importantly contributed to the
identification of possible chemotherapeutic agents for a certain number of cancers, with a few even moved to clinical trials. Since many of the Ca\(^{2+}\) channels/transporters/pumps may play a role in normal physiology and normal cell functions, one challenge in drug development targeting these Ca\(^{2+}\) signaling proteins is to identify their cancer specific properties. Moreover, it is also important to identify a set of the channels that contribute to the tumor development in a given patient tissue. Structure-based rational design of more potent, more specific compounds targeting Ca\(^{2+}\) channels/transporters/pumps will likely provide promising leads for novel cancer treatment in the coming years.

Acknowledgements

The research in Pan's laboratory is partially supported by NIH R01-CA185055 (to Zui Pan) and Chaochu Cui received postgraduate student training of internationalization level promotion program from Sun Yat-sen University (02300-52114000). The research in Pan’s laboratory is partially supported by NIH R01-CA185055 (to Zui Pan) and Chaochu Cui received postgraduate student training of internationalization level promotion program from Sun Yat-sen University (02300-52114000). The research in Pan’s laboratory is partially supported by NIH R01-CA185055 (to Zui Pan) and Chaochu Cui received postgraduate student training of internationalization level promotion program from Sun Yat-sen University (02300-52114000).

References

1. Berridge MJ, Lipp P, Bootman MD. The versatility and universality of calcium signalling. *Nat Rev Mol Cell Biol* 2000;1:11–21.
2. Csordas G, Varnai P, Golenar T, Roy S, Purkins G, Schneider TG, et al. Imaging interorganelle contacts and local calcium dynamics at the ER-Mitochondrial interface. *Mol Cell* 2010;39:121–32.
3. Parkash J, Asotra K. Calcium wave signaling in cancer cells. *Life Sci* 2010;87:587–95.
4. McConkey DJ, Orrenius S. The role of calcium in the regulation of energy metabolism. *Biochem Biophys Res Commun* 1997;239:357–66.
5. Baudouin-Legros M, Brouillard F, Tondelier D, Hinzpter A, Edelman A. Effect of ouabain on CFTR gene expression in human Calu-3 cells. *Am J Physiol Cell Physiol* 2003;284:C620–6.
6. Zhu H, Zhang H, Jin F, Fang M, Huang M, Yang CS, et al. Elevated Orai1 expression mediates tumor-promoting intracellular Ca\(^{2+}\) oscillations in human esophageal squamous cell carcinoma. *Oncotarget* 2014;5:3455–71.
7. Parekh AB. Decoding cytosolic Ca\(^{2+}\) oscillations. *Trends Biochem Sci* 2011;36:78–87.
8. Berridge MJ. The AM and FM of calcium signalling. *Nature* 1997;386:759–60.
9. Smeekers E, Uhlen P. Frequency decoding of calcium oscillations. *Biochim Biophys Acta* 2013.
10. Cullen PJ. Calcium signalling: the ups and downs of protein kinase C. *Curr Biol* 2003;13:R699–701.
11. Hu Q. [Ca\(^{2+}\)i] Oscillation frequency regulates agonist-stimulated NF-κB transcriptional activity. *J Biol Chem* 1999;274:33995–8.
12. Dolmetsch RE, Xu K, Lewis RS. Calcium oscillations increase the efficiency and specificity of gene expression. *Nature* 1998;392:933–6.
13. Kondratskyi A, Yassine M, Kondratska K, Skryma R, Slomiannyc N, Prevarskaya N. Calcium-permeable ion channels in control of autophagy and cancer. *Front Physiol* 2013;4:272.
14. Gu J, Liu H, Fu T, Xu Y. Thapsigargin increases apoptotic cell death in human hepatoma BEL-7404 cells. *Cell Res* 1995;5:59–65.
15. Vandewalle B, Hornez L, Watzke N, Revillon F, Lefebvre J. Vitamin-D\(^3\) and breast-tumor cell growth: effect on intracellular calcium and apoptosis. *Int J Cancer* 1995;61:806–11.
16. Liu LH, Boivin GP, Prasad V, Periasamy M, Shull GE. Squamous cell tumors in mice heterozygous for a null allele of Atp2a2, encoding the sarcoplasmic reticulum Ca\(^{2+}\)-ATPase isoform 2 Ca\(^{2+}\) pump. *J Biol Chem* 2001;276:26737–40.
17. Roderick HL, Cook SJ. Ca\(^{2+}\) signalling checkpoints in cancer: remodelling Ca\(^{2+}\) for cancer cell proliferation and survival. *Nat Rev Cancer* 2008;8:361–75.
Targeting calcium signaling in cancer therapy

38. Aung CS, Kruger WA, Poronnik P, Roberts-Thomson SJ, Monteith GR. Plasma membrane Ca\(^{2+}\)-ATPase expression during colon cancer cell line differentiation. *Biochem Biophys Res Commun* 2007;355:932–6.

39. Saito K, Utazawa K, Endo Y, Kato Y, Nakashima D, Ogawara K, et al. Plasma membrane Ca\(^{2+}\)-ATPase isomorph 1 down-regulated in human oral cancer. *Oncol Rep* 2006;15:49–55.

40. Caterall WA. Structure and regulation of voltage-gated Ca\(^{2+}\) channels. *Annu Rev Cell Dev Biol* 2000;16:521–55.

41. Wang CY, Lai MD, Phan NN, Sun Z, Lin YC. Meta-analysis of clinical pharmacology. LXXVI. Current progress in the mammalian T-type calcium channels. *Cell Physiol Biochem* 2010;26:797–808.

42. Kale VP, Amin SG, Pandey MK. Targeting ion channels for cancer therapy by repurposing the approved drugs. *Biochim Et Biophys Acta (BBA)-Biomembr* 2015;1848:2747–55.

43. Dziegielewskas B, Gray LS, Dziegielewski J. T-type calcium channels blockers as new tools in cancer therapies. *Pflugers Arch* 2014;466:801–10.

44. Ohkubo T, Yamazaki J. T-type voltage-activated calcium channel Cav3.1, but not Cav3.2, is involved in the inhibition of proliferation and apoptosis in MCF-7 human breast cancer cells. *Int J Oncol* 2012;41:267–75.

45. Gackiere F, Biélaux G, Delcourt P, van Coppenolle F, Katsogiannou M, Dewailly E, et al. Cav3.2 T-type calcium channels are involved in calcium-dependent secretion of neuroendocrine prostate cancer cells. *J Biol Chem* 2008;283:10162–73.

46. Latour I, Lowd WF, Beedle AM, Hamid J, Sutherland GR, Zamponi GW. Expression of T-type calcium channel splice variants in human glioma. *Glia* 2004;48:112–9.

47. Wu LJ, Sweet TB, Clapham DE. International union of basic and clinical pharmacology. LXXVI. Current progress in the mammalian TRP ion channel family. *Pharmacol Rev* 2010;62:381–404.

48. Nilius B. TRP channels in disease. *Biochim Biophys Acta* 2007;1772:805–12.

49. El Hiani Y, Lehen’kyi V, Ouadid-Ahidouch H, Ahidouch A. Activation of the calcium-sensing receptor by high calcium induced breast cancer cell proliferation and TRPC1 cation channel over-expression potentially through EGFR pathways. *Arch Biochem Biophys* 2009;486:58–63.

50. Yang SL, Cao Q, Zhou KC, Feng YJ, Wang YZ. Transient receptor potential channel C3 contributes to the progression of human ovarian cancer. *Oncogene* 2009;28:1320–8.

51. Aydar E, Yeo S, Djangouz M, Palmer C. Abnormal expression, localization and interaction of canonical transient receptor potential ion channels in human breast cancer cell lines and tissues: a potential target for breast cancer diagnosis and therapy. *Cancer Cell Int* 2009;9:23.

52. Pavard-Barrat I, Zhang L, Barratt G. TRP channels in cancer. *Biochim Biophys Acta* 2007;1772:937–46.

53. Ouadid-Ahidouch H, Dhennin-Duthille I, Gautier M, Sevestre H, Ahidouch A. TRP channels: diagnostic markers and therapeutic targets for breast cancer. *Cancer Lett* 2009;277:35–46.

54. Dhennin-Duthille I, Gautier M, Baouzi M, Guibert M, Vaudry D, et al. High expression of transient receptor potential channels in human breast cancer epithelial cells and tissues: correlation with pathological parameters. *Cell Physiol Biochem* 2011;28:813–22.

55. Dhennin-Duthille I, Gautier M, Dhennin-Duthille I, Haren N, Sevestre H, Ouadid-Ahidouch H. Evidence that TRPM7 is required for breast cancer cell proliferation. *Am J Physiol Cell Physiol* 2009;297:C493–502.

56. Guibert A, Gautier M, Dhennin-Duthille I, Telliez MS, Sevestre H, et al. Estrogen regulation of TRPM8 expression in breast cancer cells. *BMC Cancer* 2010;10:212.

57. Clark K, Middelbeck J, van Leeuwen FN. Interplay between TRP channels and the cytoskeleton in health and disease. *Eur J Cell Biol* 2008;87:631–40.

58. Bergmeier W, Weidinger C, Zie E, Feske S. Emerging roles of store-operated Ca\(^{2+}\) entry through STIM and Orai proteins in immunity, hemostasis and cancer. *Channels (Austin)* 2013;7:579–91.

59. Yang S, Zhang JI, Huang XY. Orai1 and STIM1 are critical for breast tumor cell migration and metastasis. *Cancer Cell* 2009;15:124–34.

60. Motiani RK, Hyzinski-Garcia MC, Zhang X, Henkel MM, Abdullaev IF, Kuo YH, et al. STIM1 and Orai1 mediate CRAC channel activity and are essential for human glioblastoma invasion. *Pflugers Arch* 2013;465:1249–60.

61. Kondratska K, Kondratskyi A, Yassine M, Lemonnier L, Lepage G, Morabito A, et al. Orai1 and STIM1 mediate SOCE and contribute to apoptotic resistance of pancreatic adenocarcinoma. *Biochim Biophys Acta* 2014;1843:2263–9.

62. Flourakis M, Lehen’kyi V, Beck B, Raphael M, Vandenbergh M, Abeele FV, et al. Orai1 contributes to the establishment of an apoptosis-resistant phenotype in prostate cancer cells. *Cell Death Dis* 2014;5:e705.

63. Dubeus C, Vanden Abeele F, Lehen’kyi V, Gkika D, Guiramet B, Lepage G, et al. Remodeling of channel-forming Orai proteins determines an oncogenic switch in prostate cancer. *Cancer Cell* 2014;26:19–32.

64. Yang N, Tang Y, Wang F, Zhang H, Xu D, Shen Y, et al. Blockade of store-operated Ca\(^{2+}\) entry inhibits hepatocarcinoma cell migration and invasion by regulating focal adhesion turnover. *Cancer Lett* 2013;330:163–9.

65. Kim JH, Lkhagvadorj S, Lee MR, Hwang KH, Chung HC, Jung JH, et al. Orai1 and STIM1 are critical for cell migration and proliferation of clear cell renal cell carcinoma. *Biochem Biophys Res Commun* 2014;448:76–82.

66. Weidinger C, Shaw PJ, Feske S. STIM1 and STIM2-mediated Ca\(^{2+}\) influx regulates antitumour immunity by CD8\(^{+}\) T cells. *EMBO Mol Med* 2013;5:1311–21.

67. Oh-Hora M, Yamashita M, Hogan PG, Sharma S, Lamperti E, Chung W, et al. Dual functions for the endoplasmic reticulum calcium sensors STIM1 and STIM2 in T cell activation and tolerance. *Nat Immunol* 2008;9:432–43.

68. Aytes A, Mollevi DG, Martinez-Iniesta M, Nadal M, Vidal A, Morales A, et al. Stromal interaction molecule 2 (STIM2) is frequently overexpressed in colorectal tumors and confers a tumor cell growth suppressor phenotype. *Mol Carcinog* 2012;51:746–53.

69. Stanisz H, Saul S, Muller CS, Kappil R, Niemeyer BA, Vogt T, et al. Inverse regulation of melanoma growth and migration by Orai1/STIM2-dependent calcium entry. *Pigment Cell Melanoma Res* 2014;27:442–53.

70. Faouzi M, Hague F, Potier M, Ahidouch A, Sevestre H, Ouadid-Ahidouch H. Down-regulation of Orai3 arrests cell-cycle progression and induces apoptosis in breast cancer cells but not in normal breast epithelial cells. *J Cell Physiol* 2011;226:542–51.

71. Ay AS, Benzerdjeb J, Sevestre H, Ahidouch A, Ouadid-Ahidouch H. Orai3 constitutes a native store-operated calcium entry that regulates non small cell lung adenocarcinoma cell proliferation. *PLoS One* 2013;8:e72889.
116. Yang B, Zhang M, Gao J, Li J, Fan L, Xiang G, et al. Small molecule RL71 targets SERCA2 at a novel site in the human colorectal cancer. *Oncotarget* 2015;6:37613–25.

117. Muscella A, Calabritto N, Vettrigna C, Fanuzzi FP, De Pascali SA, Strollo C, et al. The platinum (II) complex [Pt(O,0′-acac)(p-acac) (DMS)] alters the intracellular calcium homeostasis in MCF-7 breast cancer cells. *Biochem Pharmacol* 2011;81:91–103.

118. Rim HK, Lee HW, Choi IS, Park JY, Choi HW, Choi JH, et al. TRP1 mediates calcium signaling in human epidermoid carcinoma A431 cells. *Bioorg Med Chem Lett* 2012;22:7123–6.

119. Kim KH, Kim D, Park JY, Jung HJ, Cho YH, Kim HK, et al. NNC 55-0396, a T-type Ca2+ channel inhibitor, inhibits angiogenesis via suppression of hypoxia-inducible factor-1α signal transduction. *J Mol Med (Berl)* 2015;93:499–509.

120. Yoshida J, Ishibashi T, Nishio M. G1 cell cycle arrest by amlopidine, a dihydropyridine Ca2+ channel blocker, in human epidermoid carcinoma A431 cells. *Biochem Pharmacol* 2007;73:943–53.

121. Garrido-Laguna I, Tan AC, Villarroel MC, Rajeshkumar N, Rubio-Viqueira B, Gray L, et al. Activity of the T-type calcium channel antagonist Mibebradil in pancreatic cancer xenografts. *Clin Cancer Res* 2008;14:2808–14.

122. Diaz-Lezama N, Hernandez-Elvira M, Sandoval A, Monroy A, Feliu R, Monjaraz E. Ghrilin enhances proliferation and increases T-type Ca2+ channel expression in PC-3 human prostate carcinoma cells. *Biochem Biophys Res Commun* 2010;403:24–9.

123. Shigetomi E, Tong X, Kwan KY, Corey DP, Khakh BS. TRPA1 channels regulate astrocyte resting calcium and inhibitory synapse efficacy through GAT-3. *Nat Neurosci* 2012;15:70–80.

124. Dasari R, De Carvalho A, Medellin DC, Middleton KN, Hague F, Volmar MN, et al. Wittig derivatization of sesquiterpenoid polygodial and optimization of 2-aminobenzimidazole derivatives as novel and potent transient receptor potential vanilloid 4 channel antagonists. *J Med Chem* 2011;54:6264–77.

125. Hwang HK, Hwang MK, Jang Y, Lee EJ, Kim JE, Oh MH, et al. 20-O-β-d-glucopyranosyl-20-(S)-protopanaxadiol, a metabolite of ginseng, inhibits colon cancer growth by targeting TRPC channel-inhibitors of TRPC4 and TRPC5 channels.

126. Yang B, Zhang M, Gao J, Li J, Fan L, Xiang G, et al. Small molecule targeting calcium signaling in cancer therapy. *ChemMedChem* 2014;9:1414–20.

127. Yang F, Xiao X, Cheng W, Yang W, Yu P, Song Z, et al. Structural mechanism underlying caspase binding and activation of the TRPV1 ion channel. *Nat Chem Biol* 2015;11:518–24.

128. Costa B, Giagnoni G, Franke C, Trovato AE, Colleoni M, Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the non-psychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation. *Br J Pharmacol* 2004;143:247–86.

129. Liu T, Wang G, Tao H, Yang Z, Wang Y, Meng Z, et al. Capsaicin mediates caspases activation and induces apoptosis through P38 and JNK MAPK pathways in human renal carcinoma. *BMC Cancer* 2016;16:790.

130. de Jong PR, Takahashi N, Harris AR, Lee J, Bertin S, Jeffries J, et al. Ion channel TRPV1-dependent activation of IP3TP1B suppresses EGF-R-associated intestinal tumorigenesis. *J Clin Invest* 2014;124:3793–806.

131. Jeng H, Lee HW, Lee YJ, Lin YL, Rassendren FA. Pharmacological characterization and molecular determinants of the activation of transient receptor potential V2 channel orthologs by 2-aminoethoxydiphenyl borate. *Mol Pharmacol* 2007;72:1258–68.

132. Velasco G, Hernandez-Tiedra S, Dávila D, Lorente M. The use of cannabinoids as anticancer agents. *Prog Neuro-Psychopharmacol Biol Psychiatry* 2016;64:259–66.

133. Nie L, Oishi Y, Doi I, Shibata H, Kojima I. Inhibition of MCF-7 breast cancer cells by a blocker of Ca2+-permeable channel. *Cell Calcium* 1997;22:75–82.

134. Thorneloe KS, Sulipizio AC, Lin Z, Figueira D, Cloake AK, McCafferty GP, et al. N-(15-(1)-(4-([2-sulfonyl]amino)-3-hydroxypropanoyl)-1-piperazinyl)[carbonyl]-3-methylbutyl)-1-henotothephene-2-carboxamide (GSK1016790A), a novel and potent transient receptor potential vanilloid 4 channel agonist induces urinary bladder contraction and hyperactivity: part I. *J Pharmacol Exp Ther* 2008;326:432–42.

135. Thorneloe KS, Baow O, Alsaid H, Jian M-Y, Costell M, Maniscalco K, et al. Discovery of orally active transient receptor potential vanilloid 4 (TRPV4) blockers for the treatment of pulmonary edema in heart failure. *Circulation* 2012;125:1383–91.

136. Nie L, Oishi Y, Doi I, Shibata H, Kojima I. Inhibition of MCF-7 breast cancer cells by a blocker of Ca2+-permeable channel. *Cell Calcium* 1997;22:75–82.

137. de Petrocellis L, Immenschuh S, Mascioli B, D’Amore P, Profi M, Ceruti S, et al. Identification of orally-bioavailable antagonists of the TRPV4 ion-channel. *Bioorg Med Chem Lett* 2015;25:4011–5.

138. Vriezen BW, van der Meer AA, Al-Salami S, Allara C, Kincaid J, et al. Identification of orally-bioavailable antagonists of the TRPV4 ion-channel. *Bioorg Med Chem Lett* 2015;25:4011–5.

139. Takezawa R, Cheng H, Beck A, Ishikawa J, Launay P, Kubota H, et al. TRPV1 agonist-induced activation of PTP1B suppresses EGFR-associated intestinal tumorigenesis. *J Biol Chem* 2005;280:10997–1006.

140. Engleman EG, et al. (−)-Englerin A is a potent and selective activator of TRPC4 and TRPC5 calcium channels. *Arq Chem Int Ed Eng* 2015;54:3787–91.

141. Carson C, Raman P, Tullai J, Xu L, Renaut M, Thomas E, et al. Englerin A agonizes the TRPC4/C5 cation channels to inhibit tumor cell line proliferation. *PLoS One* 2015;10:e0127498.

142. Miller M, Shi J, Zhu Y, Kustov M, Tian JB, Stevens A, et al. Identification of ML204, a novel potent antagonist that selectively modulates native TRPC4/5 ion channels. *J Biol Chem* 2011;286:34346–46.

143. Seo K, Rainer PP, Hahn VS, Lee DI, Jo SH, Andersen A, et al. Combined TRPC3 and TRPC6 blockade by selective small-molecule or genetic deletion inhibits pathological cardiac hypertrophy. *Proc Natl Acad Sci U S A* 2014;111:1551–6.

144. Madan E, Gogna R, Keppler B, Pati U. p53 increases intra-cellular calcium release by transcriptional regulation of calcium channel TRPC6 in GaQ3-treated cancer cells. *PLoS One* 2013;8:e71016.
Targeting calcium signaling in cancer therapy

Joachim JR, Marek M, editors. New Comprehensive Biochemistry. Amsterdam: Elsevier; 2007. p. 127–66.

190. Strobl JS, Kirkwood KL, Lantz TK, Lewine MA, Peterson VA, Worley 3rd JF. Inhibition of human breast cancer cell proliferation in tissue culture by the neuroleptic agents pimozide and thioridazine. Cancer Res 1990;50:5399–405.

191. Krouse AJ, Gray L, Macdonald T, McCray J. Repurposing and repurposing of mibefradil, an antihypertensive, for cancer: a case study. Assay Drug Dev Technol 2015;13:650–3.

192. Bruce JIE, Elliott AC. Pharmacological evaluation of the role of cytochrome P450 in intracellular calcium signalling in rat pancreatic acinar cells. Br J Pharmacol 2000;131:761–71.

193. Merritt JE, Armstrong WP, Benham CD, Hallam TJ, Jacob R, Jaxa-Chamiec A, et al. SK&F 96365, a novel inhibitor of receptor-mediated calcium entry. Biochem J 1990;271:515–22.

194. Zeng B, Yuan C, Yang X, Atkin SL, Xu SZ. TRPC channels and differences in channel composition. TRPC3 channels in receptor-activated and store-operated modes. J Biol Chem 2011;286:9429–42.

195. Schleifer H, Doleschal B, Lichtenegger M, Oppenrieder R, Derler I, Frischauer I, et al. Novel pyrazole compounds for pharmacological discrimination between receptor-operated and store-operated Ca2+ entry pathways. Br J Pharmacol 2012;167:1712–22.

196. Zitt C, Strauss B, Schwarz EC, Spaeth N, Rast G, Hatzelmann A, et al. Potent inhibition of Ca2+ release-activated Ca2+ channels and T-lymphocyte activation by the pyrazole derivative BTP2. J Biol Chem 2004;279:12427–37.

197. Ng SW, di Capite J, Singaravelu K, Parekh AB. Sustained activation of the tyrosine kinase Syk by antigen in mast cells requires local Ca2+ influx through Ca2+ release-activated Ca2+ channels. J Biol Chem 2008;283:31348–55.

198. Li J, McKeown L, Ojelabi O, Stacey M, Foster R, O'Regan D, et al. Nanomolar potency and selectivity of a Ca2+ release-activated Ca2+ channel inhibitor against store-operated Ca2+ entry and migration of vascular smooth muscle cells. Br J Pharmacol 2011;164:382–93.

199. Ramos S, Grigoryev S, Rogers E, Roos J, Stauderman K, et al. CM3457, a potent and selective oral CRAC channel inhibitor, suppresses T and mast cell function and is efficacious in rat models of arthritis and asthma. J Immunol 2012;188:72.3.

200. Lin FF, Elliott R, Colonbero A, Gaida K, Kelley L, Moks A, et al. Generation and characterization of fully human monoclonal anti-bodies against human Orai1 for autoimmune disease. J Pharmacol Exp Ther 2013;345:225–38.

201. Cox JH, Russell S, Sondergaard H, Roepstorff K, Bui JV, Deer JR, et al. Antibody-mediated targeting of the Orai1 calcium channel inhibits T cell function. PLoS One 2013;8:e82944.